Effects of reslizumab on asthma control questionnaire-7 (ACQ-7) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

Slides:

Advertisements

Similar presentations

Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to previous chronic obstructive.

Advertisements

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to chronic obstructive pulmonary disease.

Change in secondary endpoints over time: (A) LS mean change from baseline in DAS28-CRP through Week 32, (B) mean change from baseline in CRP through Week.

Echocardiography view

Results of the AweScoreCF questionnaire completed by 23 adult cystic fibrosis (CF) patients 1 month before and 3 months after initiating ivacaftor–lumacaftor.

Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma

Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.

Serial imaging while on immunosuppressive therapy (two subjects).

Ventilatory and cerebrovascular responses to hyperoxic hypercapnia.

Compliance of the respiratory system (Crs) at baseline and 0 h, 1 h and 2 h following lung volume recruitment. a) Absolute Crs in the respiratory muscle.

Flowchart for calculating the relative risk (RR) for cancer X and lung cancer (LC). Flowchart for calculating the relative risk (RR) for cancer X and lung.

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Change from baseline in trough forced expiratory volume in 1 s (FEV1) (per-protocol population). Change from baseline in trough forced expiratory volume.

Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %

Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.

Composition of microbial communities in induced sputa of healthy and mild, moderate, severe or very severe (end-stage) lung disease affected individuals.

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

Survival without tracheostomy

Survey scores for Partners In Health (PIH-NL), Patient Activation Measure (PAM13-NL), Euroquol-5D3L (EQ-5D3L) and Short Self-Management Ability Scale (SMAS-s)

Effects of reslizumab on: (a) clinical asthma exacerbation (CAE) rates; (b) rates of clinical asthma exacerbation requiring oral corticosteroids (OCS);

Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

Distribution of lower extremity artery disease (LEAD) Fontaine stages over the combined chronic obstructive pulmonary disease (COPD) Global Initiative.

Bland–Altman plot of slopes of measurement 1 versus 2

Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to exacerbation history (intent-to-treat.

Bland–Altman comparison of lung clearance index (LCI) from multiple breath wash-out following open and modified closed circuit wash-in for both healthy.

A) Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio as a function of age showing individuals with FEV1/FVC ratio less than the.

Effects of reslizumab on asthma quality of life questionnaire (AQLQ) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

Change from baseline following beclomethasone/formoterol and placebo in a) platelet–monocyte aggregate formation, b) P-selectin expression and c) platelet.

A) Peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) response following once-daily tiotropium Respimat add-on to medium-dose.

Examination of the prevalence of asthma exacerbations and loss of asthma control throughout pregnancy in women with asthma. Examination of the prevalence.

Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

Change from baseline in (A) E-RS total score and (B) E-RS cough and sputum domain score over the study period in ATTAIN and the active-comparator study.

A white elephant or the elephant in the room

Least squares (LS) mean change from baseline (95% CI) in St George's Respiratory Questionnaire (SGRQ) Total score according to chronic obstructive pulmonary.

Kaplan–Meier curves of long-term survival in young (

A) The flexible 1.9 mm diameter and 900 mm length cryoprobe, b) connected to the cryotherapy equipment. c) Marks on the distal area of the probe (1 cm.

Most frequent words and phrases based on user comments about the registry. Most frequent words and phrases based on user comments about the registry. Word.

Summary of the specialist nurse coordinated multidisciplinary team (MDT) pathway at University Hospital Southampton Foundation Trust, Southampton, UK.

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to exacerbation history (intent-to-treat.

A) Healthcare utilisation, b) short form (SF)-12 scores and c) work productivity and activity impairment in patients with asthma (▓) and diabetes (▪) in.

Average mean arterial pressure (Pa) during lung volume recruitment (LVR) in (a) the respiratory muscle weakness (RMW) group and (b) the control group.

a) Mortality per time point (p<0

Change from baseline in the severity of morning cough and severity of difficulty bringing up phlegm in the morning over the study period in the active-comparator.

Individual plots of overall Standardised Asthma Quality of Life Questionnaire (AQLQ(S)) scores in each Global Initiative for Asthma level of asthma control.

Scatter plot of the % change versus baseline in pulmonary function test results at a) 4 months and b) the end of the study versus the analyte concentration.

A family-based pulmonary rehabilitation (PR) programme enhanced the coping resources of the families of chronic obstructive pulmonary disease patients.

Patients' and partners' experience of anxiety in the Netherlands (NL) and Germany (GE), based on the Generalised Anxiety Disorder-single item questionnaire.

Individual plots of Standardised Asthma Quality of Life Questionnaire (AQLQ(S)) scores for the symptoms domain in each Global Initiative for Asthma level.

Changes in St. George's Respiratory Questionnaire (SGRQ) scores from baseline to 12 weeks for total samples (n=277), quitters (n=183) and continuous smokers.

Individual plots of Standardised Asthma Quality of Life Questionnaire (AQLQ(S)) scores for the activity limitation domain in each Global Initiative for.

Effect of omalizumab on change from baseline (B) in a) total asthma symptom score, b) total rhinitis symptom score, and c) combined asthma and rhinitis.

Forest plot of adjusted odds ratios (with 95% confidence intervals) from multivariable multinomial logistic regression analysis (table 4), by number of.

Α1-Antitrypsin (AAT) therapy considerations: a) practical difficulties with AAT infusions; b) concerns regarding AAT doses >60 mg·kg−1 per week. α1-Antitrypsin.

Weekly pneumococcal community-acquired pneumonia incidence rates over 5 years, with delineated school holiday periods by year. a) Year 1 (September 2008–2009).

Differences in a) functional residual capacity (FRC) and b) lung clearance index (LCI) when using all trials in comparison with only the first two trials.

Percentage of women using snus and/or cigarette smoke during pregnancy based on self-reported time for stopping from those who completed both 18-week and.

Physician perspectives on self-administration of i. v. α1-antitrypsin

Distribution of patients in the first- or second-year follow-up according to the number of acute exacerbations of chronic obstructive pulmonary disease.

Change in the regular use of inhaled corticosteroids (as a single inhaler or in combination; any use in the last 12 months) in participants with persistent.

Bland–Altman comparison of functional residual capacity (FRC) measured from multiple breath wash-out following open and modified closed circuit wash-in.

Composition of the most common clusters at the a) onset of the first acute respiratory tract infection (swab A) and b) 3 weeks later (swab B) illustrated.

Scatterplots showing baseline correlation between forced expiratory volume in 1 s (FEV1) % pred and a) COPD Assessment Test (CAT), b) Clinical COPD Questionnaire.

Comparison of cancer-specific survival in patients with nonsmall cell lung cancer detected incidentally by computed tomography (CT) (n=41) or chest radiography.

Prevalence of acute myocardial infarction (AMI) or other cardiovascular events (CVEs) according to a) Pneumonia Severity Index (PSI) risk classes and b)

Effects of reslizumab on lung function (forced expiratory volume in 1 s; FEV1) in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of.

Percentage of positive results by pathogen among study patients with identified pathogens. “Other” includes respiratory viruses, Stenotrophomonas, Prevotella,

Modified Delphi process used to reach a consensus among experts in severe asthma regarding the degree of benefit of biomarker-based adjustment of corticosteroid.

Biomarker levels at hospital admission, clinical stabilisation and 6-week follow-up in 267 hospitalised patients with community-acquired pneumonia. a)

Median (95% CI) exhaled nitric oxide fraction (FeNO) at each visit for the two intervention groups. Median (95% CI) exhaled nitric oxide fraction (FeNO)

Geometric mean (95% CI) response dose ratio (RDR) at each visit for the two intervention groups. Geometric mean (95% CI) response dose ratio (RDR) at each.

Presentation transcript:

Effects of reslizumab on asthma control questionnaire-7 (ACQ-7) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab on asthma control questionnaire-7 (ACQ-7) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. (a) Changes from baseline ACQ-7 score at week 16 and week 52 and (b) changes relative to placebo throughout the study. Increase in control is represented by a decrease in ACQ-7 score [16, 19]. LS: least square. Guy Brusselle et al. ERJ Open Res 2017;3:00004-2017 ©2017 by European Respiratory Society